dync2li1 Antibody

What is DYNC2LI1 and why is it important in cellular research?

DYNC2LI1, also known as D2LIC or LIC3, functions as a crucial component of the dynein-2 complex responsible for retrograde intraflagellar transport. This protein plays a vital role in cilia biogenesis and maintenance by facilitating the movement of cargo from the ciliary tip back to the cell body . Research has demonstrated that DYNC2LI1 contains a P-loop nucleoside triphosphate hydrolases domain (position aa 30-240) including a Dynein light intermediate chain domain (position aa 30-163) . DYNC2LI1 is essential for converting ATP chemical energy into mechanical movement along microtubules, making it critical for cellular homeostasis . Mutations in DYNC2LI1 have been linked to various skeletal ciliopathies, including Jeune syndrome, highlighting its significance in human development and disease .

What applications are DYNC2LI1 antibodies commonly used for?

DYNC2LI1 antibodies are versatile tools in molecular and cellular biology research with multiple validated applications:

For optimal results, researchers should select antibodies validated for their specific application and experimental system, as reactivity can vary between human and mouse samples .

What are the expression patterns of DYNC2LI1 in different tissues?

DYNC2LI1 demonstrates a ubiquitous expression pattern across tissues, with notable variations in expression levels:

• Highest expression: chondrocytes, brain, kidney, lung, and testes

• Similar expression levels in most adult and fetal tissues

• Higher expression in fetal brain, kidney, and lungs compared to adult tissues

• Multiple isoforms are expressed, with the two longest isoforms being predominant in most tissues

This expression pattern aligns with the function of DYNC2LI1 in cilia, which are present in most cell types but particularly important in specialized tissues such as brain, kidney, and developing skeletal structures . When designing experiments, researchers should consider these tissue-specific expression patterns, especially when studying developmental processes or ciliopathies affecting particular organ systems.

What controls should be included when using DYNC2LI1 antibodies?

When designing experiments with DYNC2LI1 antibodies, include these essential controls:

• Positive controls:

  • HEK-293T cells, L02 cells, and mouse brain tissue have confirmed DYNC2LI1 expression

  • Chondrocytes show particularly high expression levels

• Negative controls:

  • DYNC2LI1 siRNA knockdown cells (ideally with confirmed 60-70% reduction)

  • Isotype-matched irrelevant antibodies to confirm specificity

• Loading/staining controls:

  • Housekeeping proteins (β-actin, GAPDH) for Western blots

  • Nuclear stain (DAPI) and cytoskeletal markers for immunofluorescence

• Validation controls:

  • Secondary antibody-only controls to verify the absence of non-specific binding

  • Peptide competition assays to confirm epitope specificity

These controls help distinguish true DYNC2LI1 signals from background or non-specific antibody binding, particularly important when studying the multiple isoforms (40 kDa, 38 kDa, 22 kDa, and 16 kDa) that have been reported .

How do different DYNC2LI1 antibody formats affect experimental design?

DYNC2LI1 antibodies are available in multiple formats that influence experimental approach:

Consider the subcellular localization of DYNC2LI1 (cytoplasm, centrosomes, basal body, and transition zone) when selecting antibody formats for immunofluorescence studies . For co-localization studies, choose fluorophores with minimal spectral overlap with other markers. If detecting multiple isoforms is important, select antibodies raised against conserved epitopes present in all isoforms.

How can DYNC2LI1 antibodies be used to study ciliopathies?

DYNC2LI1 antibodies provide valuable tools for investigating ciliopathies through multiple methodological approaches:

• Diagnostic immunostaining:

  • Compare DYNC2LI1 localization patterns in patient-derived cells versus controls

  • Analyze cilia morphology alterations using DYNC2LI1 and other ciliary markers

  • Quantify changes in retrograde transport through accumulation of IFT proteins

• Functional studies:

  • Use DYNC2LI1 antibodies to assess protein expression in patient samples carrying DYNC2LI1 mutations

  • Evaluate the impact of mutations on protein-protein interactions within the dynein-2 complex

  • Monitor changes in DYNC2LI1 localization following treatment with potential therapeutic compounds

Research has demonstrated that DYNC2LI1 depletion leads to specific phenotypes including reduced cilia length (1.42 μm versus 1.83 μm in controls) and broadened ciliary tips (14% abnormal versus 6% in controls) . These cellular phenotypes correspond to clinical manifestations in patients with DYNC2LI1 mutations, making antibody-based detection critical for understanding genotype-phenotype correlations in ciliopathies.

What methodological approaches optimize DYNC2LI1 detection in immunofluorescence studies?

For high-quality immunofluorescence detection of DYNC2LI1, implement these advanced methodological considerations:

• Sample preparation:

  • Perform serum starvation (5 days recommended) to induce ciliogenesis prior to fixation

  • Use 4% paraformaldehyde fixation to preserve ciliary structures

  • Employ mild permeabilization to maintain delicate ciliary structures

• Antibody optimization:

  • Test both monoclonal (e.g., H-4 clone) and polyclonal antibodies for optimal signal-to-noise ratio

  • Validate antibody specificity using siRNA knockdown controls

  • Use antibodies recognizing different epitopes for confirmation of localization patterns

• Imaging considerations:

  • Employ super-resolution microscopy for detailed ciliary substructure analysis

  • Implement z-stack acquisition to capture the entire ciliary structure

  • Use deconvolution algorithms to enhance signal clarity at ciliary transition zones

When examining ciliary morphology changes following DYNC2LI1 depletion or mutation, careful quantification of cilia length, width, and tip morphology is essential, as broadened ciliary tips represent a specific phenotype of retrograde IFT defects .

How can researchers effectively analyze DYNC2LI1 isoform expression?

DYNC2LI1 exists in multiple alternatively spliced isoforms with different molecular weights (40 kDa, 38 kDa, 22 kDa, and 16 kDa) . To effectively analyze these isoforms:

• Gel and transfer optimization:

  • Use gradient gels (4-15%) to effectively separate different sized isoforms

  • Adjust transfer conditions for efficient transfer of both large and small isoforms

  • Consider using PVDF membranes for better retention of smaller isoforms

• Antibody selection:

  • Choose antibodies recognizing epitopes present in all isoforms for pan-isoform detection

  • Use isoform-specific antibodies when available for targeted analysis

  • Verify epitope location relative to alternatively spliced regions

• Quantification approach:

  • Normalize each isoform separately against loading controls

  • Calculate relative ratios between isoforms to detect shifts in expression patterns

  • Compare isoform distribution across different tissues or experimental conditions

Researching DYNC2LI1 isoform expression is particularly relevant since mutations affecting specific isoforms can lead to different phenotypic outcomes. Evidence suggests the two longest isoforms are predominantly expressed in most tissues and are likely the most relevant for ciliary function .

What are the most effective methods for evaluating DYNC2LI1 interactions with other dynein complex components?

To rigorously investigate DYNC2LI1 interactions within the dynein-2 complex:

• Co-immunoprecipitation approaches:

  • Use agarose-conjugated DYNC2LI1 antibodies for direct pull-down of protein complexes

  • Perform reciprocal IP with antibodies against known interaction partners (DYNC2H1)

  • Include detergent optimization to maintain intact protein complexes

• Proximity ligation assays:

  • Combine DYNC2LI1 antibodies with antibodies against putative interaction partners

  • Quantify interaction signals at different subcellular locations

  • Compare interaction patterns between wild-type and mutant proteins

• FRET-based approaches:

  • Use fluorophore-conjugated antibodies against DYNC2LI1 and interaction partners

  • Measure energy transfer efficiency to calculate molecular proximity

  • Apply to live cell imaging for dynamic interaction studies

The interaction between DYNC2LI1 and DYNC2H1 is particularly important for forming the functional dynein-2 complex essential for retrograde IFT . Disruption of this interaction through mutations can lead to ciliopathies, making interaction studies valuable for understanding disease mechanisms.

How can DYNC2LI1 antibodies be used to assess retrograde intraflagellar transport defects?

DYNC2LI1 antibodies provide powerful tools for analyzing retrograde IFT defects through these methodological approaches:

• IFT protein accumulation analysis:

  • Immunostain for DYNC2LI1 and IFT-B complex proteins to visualize transport defects

  • Quantify fluorescence intensity along the ciliary length and at ciliary tips

  • Compare distribution patterns between normal and affected cells

• Live-cell imaging strategies:

  • Use fluorescently tagged DYNC2LI1 antibody fragments for dynamic transport studies

  • Combine with photobleaching techniques to measure transport rates

  • Track individual particles for detailed kinetic analysis

• Biochemical fractionation:

  • Separate ciliary fractions and analyze DYNC2LI1 distribution

  • Compare with distribution of IFT-B proteins to identify transport defects

  • Assess post-translational modifications that may affect transport functions

Research has shown that DYNC2LI1 depletion results in characteristic accumulation of IFT-B complex proteins at ciliary tips, consistent with retrograde transport defects . This phenotype mirrors findings in patients with dynein-2 complex mutations, making it a valuable endpoint for assessing therapeutic interventions in ciliopathies.

What are common challenges in Western blot detection of DYNC2LI1 and how can they be addressed?

Researchers frequently encounter these challenges when detecting DYNC2LI1 by Western blot:

• Multiple band detection:

  • Problem: DYNC2LI1 exists in multiple isoforms (37-40 kDa, 22 kDa, and others)

  • Solution: Use gradient gels (4-15%) for better separation; verify bands with recombinant protein controls; consider using isoform-specific antibodies when targeting specific variants

• Low signal intensity:

  • Problem: DYNC2LI1 expression varies across tissues and may be low in some samples

  • Solution: Increase protein loading (50-80 μg); use enhanced chemiluminescence detection; consider signal amplification systems; optimize antibody concentration (1:500-1:2000 recommended)

• Non-specific binding:

  • Problem: Some antibodies may cross-react with other dynein components

  • Solution: Increase blocking time/concentration; validate specificity with DYNC2LI1 knockdown controls; use more stringent wash conditions; consider monoclonal antibodies for increased specificity

• Degradation products:

  • Problem: Additional bands may represent degradation fragments

  • Solution: Use fresh samples; add complete protease inhibitor cocktails during extraction; reduce processing time; maintain samples at 4°C throughout preparation

Including positive controls (HEK-293T cells, L02 cells, or mouse brain tissue) in Western blot experiments is essential for validating DYNC2LI1 detection .

How can background issues in DYNC2LI1 immunofluorescence be minimized?

To achieve clean, specific immunofluorescence staining for DYNC2LI1:

• Fixation optimization:

  • Problem: Inappropriate fixation can create artifacts or mask epitopes

  • Solution: Compare 4% PFA with methanol fixation; optimize fixation time (10-15 minutes typically optimal); perform antigen retrieval if necessary

• Blocking enhancement:

  • Problem: Insufficient blocking leads to high background

  • Solution: Extend blocking time to 1-2 hours; use combination blockers (BSA plus normal serum); include 0.1-0.3% Triton X-100 in blocking buffer for better penetration

• Antibody specificity:

  • Problem: Non-specific antibody binding to cellular structures

  • Solution: Pre-absorb antibodies with fixed cells lacking DYNC2LI1; titrate antibody concentration extensively; validate specificity with siRNA knockdown controls (target 60% reduction)

• Detection system optimization:

  • Problem: High background with secondary antibodies

  • Solution: Use highly cross-adsorbed secondary antibodies; include 0.05% Tween-20 in wash buffers; optimize secondary antibody concentration; include secondary-only controls

When studying DYNC2LI1 localization at cilia, co-staining with basal body markers (e.g., γ-tubulin) and ciliary markers (e.g., acetylated tubulin) provides important reference points for accurate localization analysis .

What strategies help resolve inconsistent results between different DYNC2LI1 antibodies?

When facing discrepancies between different DYNC2LI1 antibodies:

• Epitope mapping:

  • Determine the exact epitopes recognized by each antibody

  • Assess whether epitopes may be masked by protein interactions or post-translational modifications

  • Select antibodies targeting different regions to provide complementary information

• Validation hierarchy:

  • Establish a validation hierarchy using genetic controls (knockout/knockdown)

  • Prioritize results from antibodies with extensive validation in relevant tissues/cells

  • Consider antibodies recognizing different epitopes as confirmatory rather than contradictory

• Application-specific optimization:

  • Different antibodies may perform optimally in different applications

  • Polyclonal antibodies (e.g., 15949-1-AP) may work better for certain applications while monoclonals (e.g., H-4) for others

  • Optimize protocols independently for each antibody rather than applying identical conditions

• Combine detection methods:

  • Use multiple antibodies simultaneously in multiplexed detection systems

  • Apply orthogonal detection methods (e.g., mass spectrometry) to resolve antibody discrepancies

  • Correlate antibody results with mRNA expression data for confirmation

Understanding that DYNC2LI1 exists in multiple isoforms with different molecular weights (37-40 kDa, 22 kDa, etc.) helps explain why different antibodies may detect distinct bands or show varying staining patterns .

How should researchers optimize siRNA knockdown experiments for DYNC2LI1 functional studies?

For robust DYNC2LI1 knockdown experiments:

• siRNA design and validation:

  • Target conserved regions present in all relevant isoforms

  • Design siRNAs that avoid regions with secondary structure

  • Validate knockdown efficiency by qRT-PCR and Western blot

  • Aim for at least 60-70% knockdown (published studies achieved ~61% knockdown)

• Experimental timing:

  • Allow 48-72 hours post-transfection before analysis

  • For cilia studies, implement 5-day serum starvation protocol after transfection

  • Design time-course experiments to capture both immediate and delayed effects

• Phenotypic analysis:

  • Measure multiple parameters including cilia length (expect reduction from ~1.83 μm to ~1.42 μm)

  • Assess cilia morphology (look for broadened ciliary tips in ~14% of cells)

  • Quantify IFT-B protein accumulation at ciliary tips

• Controls and rescue experiments:

  • Include scrambled siRNA controls processed identically

  • Perform rescue experiments with siRNA-resistant DYNC2LI1 constructs

  • Include positive controls targeting genes with known ciliary phenotypes

What are the best approaches for quantifying DYNC2LI1 localization changes in response to experimental treatments?

To accurately quantify DYNC2LI1 localization changes:

• Image acquisition standardization:

  • Use identical acquisition parameters across all experimental conditions

  • Acquire images below saturation to enable accurate intensity measurements

  • Collect sufficient z-stacks to capture the entire structure of interest

• Quantitative analysis methods:

  • Implement line scan analysis along ciliary length to generate intensity profiles

  • Develop region-of-interest (ROI) analysis for specific compartments (base, shaft, tip)

  • Apply colocalization algorithms when studying DYNC2LI1 with other proteins

• Statistical approaches:

  • Analyze sufficient cells per condition (minimum 50-100 recommended)

  • Apply appropriate statistical tests (Mann-Whitney U test for non-parametric data)

  • Report effect sizes in addition to p-values for meaningful interpretation

• Visualization and reporting:

  • Present data as both representative images and quantitative graphs

  • Include distribution plots rather than just means to capture population heterogeneity

  • Report exact p-values and confidence intervals for robust interpretation

These approaches have successfully detected significant differences in cilia morphology following DYNC2LI1 depletion, with statistical significance at p = 1.205 × 10^-6 for cilia length differences and p = 0.028 for ciliary tip abnormalities .

How can DYNC2LI1 antibodies contribute to therapeutic development for ciliopathies?

DYNC2LI1 antibodies offer valuable tools for therapeutic development through:

• Target validation approaches:

  • Use antibodies to confirm expression and localization of DYNC2LI1 in disease-relevant tissues

  • Correlate protein expression with disease progression in patient samples

  • Validate cellular phenotypes in patient-derived cells using quantitative immunofluorescence

• Compound screening applications:

  • Develop high-content screening assays measuring DYNC2LI1 localization

  • Assess restoration of retrograde IFT using antibody-based detection of IFT proteins

  • Monitor normalization of cilia length and morphology following treatment

• Biomarker development:

  • Evaluate DYNC2LI1 expression patterns as potential prognostic indicators

  • Develop antibody-based diagnostics for ciliopathy subtypes

  • Track treatment response through changes in DYNC2LI1-dependent cellular phenotypes

DYNC2LI1 mutations have been linked to ciliopathies including Jeune syndrome, characterized by skeletal abnormalities . Therapeutic approaches targeting dynein-2 complex function or expression represent promising avenues for treating these currently incurable disorders.

What novel microscopy techniques can enhance DYNC2LI1 imaging in research?

Advanced microscopy approaches for DYNC2LI1 research include:

• Super-resolution techniques:

  • Structured illumination microscopy (SIM) provides ~120 nm resolution for detailed ciliary substructures

  • STED microscopy enables visualization of DYNC2LI1 distribution within transition zones

  • Single-molecule localization microscopy (PALM/STORM) reveals nanoscale organization of dynein complexes

• Live-cell imaging innovations:

  • Lattice light-sheet microscopy minimizes phototoxicity for extended imaging

  • SPT (single-particle tracking) enables following individual dynein complexes during transport

  • FRAP (fluorescence recovery after photobleaching) quantifies DYNC2LI1 dynamics at ciliary compartments

• Correlative microscopy approaches:

  • CLEM (correlative light and electron microscopy) links DYNC2LI1 localization to ultrastructural features

  • FIB-SEM (focused ion beam-scanning electron microscopy) provides 3D context at nanometer resolution

  • Expansion microscopy physically enlarges samples for enhanced optical resolution of ciliary structures

These techniques can reveal previously inaccessible details about DYNC2LI1 distribution and dynamics, potentially uncovering new mechanisms of ciliopathy pathogenesis and identifying novel therapeutic targets.

How might DYNC2LI1 antibodies be incorporated into multi-omics research strategies?

Integrating DYNC2LI1 antibodies into multi-omics frameworks:

• Antibody-based proteomics:

  • Use DYNC2LI1 antibodies for immunoprecipitation followed by mass spectrometry to identify novel interactors

  • Apply proximity labeling (BioID, APEX) with DYNC2LI1 antibodies to map local protein neighborhoods

  • Develop targeted proteomics assays for quantifying DYNC2LI1 complexes in limited samples

• Spatial multi-omics:

  • Combine DYNC2LI1 immunostaining with in situ transcriptomics to correlate protein localization with local gene expression

  • Implement multiplexed protein detection to analyze dynein-2 complex components simultaneously

  • Apply spatial proteomics to map DYNC2LI1 distribution across subcellular compartments

• Functional genomics integration:

  • Correlate CRISPR screens with DYNC2LI1 antibody-based phenotypic readouts

  • Link genetic variants to altered DYNC2LI1 expression or localization patterns

  • Combine transcriptomics with DYNC2LI1 protein expression data to identify regulatory networks

These integrated approaches can reveal how DYNC2LI1 functions within broader cellular networks and identify novel mechanisms contributing to ciliopathies beyond direct effects on retrograde IFT.

What are promising future directions for DYNC2LI1 research in developmental biology?

Emerging frontiers for DYNC2LI1 research in development include:

• Tissue-specific functions:

  • Investigate tissue-specific roles of different DYNC2LI1 isoforms during development

  • Explore differential expression patterns between fetal and adult tissues (particularly in brain, kidney, and lung)

  • Determine how DYNC2LI1 functions in specialized ciliated tissues like the developing growth plate

• Developmental signaling integration:

  • Examine DYNC2LI1's role in Hedgehog signaling during skeletal development

  • Investigate interactions between retrograde IFT and Wnt signaling pathways

  • Analyze how ciliary DYNC2LI1 function influences developmental morphogen gradients

• Evolutionary perspectives:

  • Compare DYNC2LI1 structure and function across model organisms

  • Investigate cilia specialization driven by DYNC2LI1 variants

  • Explore the evolution of dynein-2 complex components and their functional conservation

Understanding DYNC2LI1's developmental roles is particularly relevant given its high expression in chondrocytes and association with skeletal ciliopathies . Developmental studies can provide insights into disease mechanisms and potentially identify critical windows for therapeutic intervention.

How can DYNC2LI1 antibodies facilitate studies of retrograde IFT dynamics?

Advanced approaches for studying retrograde IFT using DYNC2LI1 antibodies:

• High-speed live imaging:

  • Combine fluorescently-tagged DYNC2LI1 antibody fragments with ultra-high-speed microscopy

  • Measure particle velocity, frequency, and processivity during retrograde transport

  • Analyze the effects of disease-causing mutations on transport kinetics

• Force measurement techniques:

  • Apply optical trapping with DYNC2LI1 antibody-coated beads to measure motor forces

  • Implement traction force microscopy to analyze dynein-2 complex mechanics

  • Correlate force generation with ATP hydrolysis activity of the P-loop domain

• Reconstitution systems:

  • Use DYNC2LI1 antibodies to purify native complexes for in vitro reconstitution

  • Develop minimal transport systems to define essential components

  • Create biomimetic cilia with purified components to study transport in controlled environments

These approaches build upon established findings that DYNC2LI1 depletion causes accumulation of IFT-B proteins at ciliary tips , providing mechanistic insights into how retrograde IFT failures lead to ciliopathies and potentially identifying points for therapeutic intervention.